Compare Illumina, Inc. (ILMN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Xylem, Inc. — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.69% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Xylem, Inc. for 50 Days on average.
| ILMN | XYL | |
|---|---|---|
Market Cap | $39.95B | $23.81B |
Volume | 3,169,503 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $293.69 | $152.95 |
52-Week Low | $91.00 | $100.92 |
Typical Hold Time | 83 Days | 50 Days |
Enterprise Value | $41.31B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
XYL trades at $102.71, up 0.86% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $9.04B in 2025 with a net income margin of 10.59%, and has beaten EPS estimates in recent quarters. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, and the appointment of a new CFO.
Outlook is supported by strong water-solutions demand and margin expansion, but risks include China weakness and higher debt. Analysts are mixed with a consensus price target of $149.13, implying significant upside from current levels, though near-term technical pressure may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
